sr141716 has been researched along with am6545 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chorvat, RJ | 1 |
| Ambudkar, SV; Bátkai, S; Godlewski, G; Kunos, G; Liu, J; Makriyannis, A; Mukhopadhyay, B; Ohnuma, S; Osei-Hyiaman, D; Pickel, J; Tam, J; Vemuri, VK | 1 |
| Järbe, TU; LeMay, BJ; Makriyannis, A; Vadivel, SK; Vemuri, VK; Zvonok, A | 1 |
| Järbe, TU; Makriyannis, A; Nikas, SP; Shukla, VG; Tai, S; Vemuri, K | 1 |
1 review(s) available for sr141716 and am6545
| Article | Year |
|---|---|
Peripherally restricted CB1 receptor blockers.
Topics: Animals; Brain; Cocaine; Drug Discovery; Humans; Liver Diseases; Metabolic Diseases; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sulfonamides | 2013 |
3 other study(ies) available for sr141716 and am6545
| Article | Year |
|---|---|
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Topics: Animals; Insulin Resistance; Leptin; Liver; Male; Mice; Mice, Inbred C57BL; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Triglycerides | 2010 |
Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
Topics: Animals; Arachidonic Acids; Cannabinoids; Discrimination, Psychological; Dose-Response Relationship, Drug; Drinking; Dronabinol; Indoles; Ligands; Male; Morpholines; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors | 2011 |
Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Topics: Animals; Body Temperature; Cannabinoid Receptor Antagonists; Cannabinoids; Disease Models, Animal; Dronabinol; Drug Tolerance; Male; Mice; Morpholines; Motor Activity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance Withdrawal Syndrome | 2015 |